- Home
- INTS vs SPAI Comparison
INTS vs SPAI Comparison
Compare INTS & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- SPAI
- Stock Information
- Founded
- INTS 2012
- SPAI 2021
- Country
- INTS United States
- SPAI United States
- Employees
- INTS 16
- SPAI N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- SPAI Industrial Specialties
- Sector
- INTS Health Care
- SPAI Health Care
- Exchange
- INTS Nasdaq
- SPAI Nasdaq
- Market Cap
- INTS 30.8M
- SPAI N/A
- IPO Year
- INTS 2023
- SPAI 2024
- Fundamental
- Price
- INTS $2.06
- SPAI $2.04
- Analyst Decision
- INTS Strong Buy
- SPAI
- Analyst Count
- INTS 3
- SPAI 0
- Target Price
- INTS $8.50
- SPAI N/A
- AVG Volume (30 Days)
- INTS 38.4K
- SPAI 45.9K
- Earning Date
- INTS 03-13-2025
- SPAI 05-15-2025
- Dividend Yield
- INTS N/A
- SPAI N/A
- EPS Growth
- INTS N/A
- SPAI N/A
- EPS
- INTS N/A
- SPAI N/A
- Revenue
- INTS N/A
- SPAI $2,169,178.00
- Revenue This Year
- INTS N/A
- SPAI N/A
- Revenue Next Year
- INTS N/A
- SPAI N/A
- P/E Ratio
- INTS N/A
- SPAI N/A
- Revenue Growth
- INTS N/A
- SPAI 35.50
- 52 Week Low
- INTS $1.50
- SPAI $1.56
- 52 Week High
- INTS $5.28
- SPAI $6.50
- Technical
- Relative Strength Index (RSI)
- INTS 46.37
- SPAI N/A
- Support Level
- INTS $1.88
- SPAI N/A
- Resistance Level
- INTS $2.18
- SPAI N/A
- Average True Range (ATR)
- INTS 0.21
- SPAI 0.00
- MACD
- INTS -0.01
- SPAI 0.00
- Stochastic Oscillator
- INTS 39.73
- SPAI 0.00
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.